All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Visual Abstract | MANIFEST trial: Updates from the EHA 2022 Congress

Jul 13, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in myelofibrosis.

During the European Hematology Association (EHA) 2022 Congress, Claire Harrison1 presented the latest results from the ongoing, open-label phase II MANIFEST trial (NCT02158858) investigating pelabresib, a bromodomain and extraterminal (BET) protein inhibitor in myelofibrosis (MF) and essential thrombocytopenia (ET).1 The study comprises four study arms: pelabresib monotherapy in MF and ET (Arms 1 and 4, respectively), pelabresib add-on to ruxolitinib in patients with MF with suboptimal response or MF progression (Arm 2), and pelabresib in combination with ruxolitinib in Janus kinase inhibitor (JAKi)-naïve patients with MF (Arm 3).1

Harrison focused on results from Arms 2 and 3, which are summarized on the visual abstract below. Pelabresib was associated with bone marrow improvements which were determined by a decrease in megakaryocyte clusters (that correlated with SVR35 response), reduced reticulin density, and an increase in erythrocytes. There were also rapid (14 days) and durable (through 24 weeks) decreases in plasma levels of NF-κB targets and inflammation-related cytokines during the treatment.1


 

Visual abstract

To download this visual abstract, click below

Download here

  1. Mascarenhas J, Kremyanskaya M, Patriarca A, et al. BET inhibitor pelabresib (CPI-0610) combined with ruxolitinib in patients with myelofibrosis—JAK inhibitor-naïve or with suboptimal response to ruxolitinib—Preliminary data from the MANIFEST study. Abstract #S198. EHA 2022 Meeting; June 9–17, 2022; Vienna, AT.